These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1259789)

  • 41. Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats.
    Melega WP; Luxen A; Perlmutter MM; Nissenson CH; Phelps ME; Barrio JR
    Biochem Pharmacol; 1990 Jun; 39(12):1853-60. PubMed ID: 2112915
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dopa decarboxylase in medullary carcinoma of the thyroid.
    Atkins FL; Beaven MA; Keiser HR
    N Engl J Med; 1973 Sep; 289(11):545-8. PubMed ID: 4146664
    [No Abstract]   [Full Text] [Related]  

  • 43. In vivo regulation of DOPA decarboxylase by dopamine receptors in rat brain.
    Cumming P; Ase A; Laliberté C; Kuwabara H; Gjedde A
    J Cereb Blood Flow Metab; 1997 Nov; 17(11):1254-60. PubMed ID: 9390657
    [TBL] [Abstract][Full Text] [Related]  

  • 44. L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro.
    Rivera-Calimlim L; Morgan JP; Dujovne CA; Bianchine JR; Lasagna L
    Biochem Pharmacol; 1971 Nov; 20(11):3051-7. PubMed ID: 5132112
    [No Abstract]   [Full Text] [Related]  

  • 45. The origin of blood 5-hydroxyindoleacetic acid following L-hydrazine-alpha-methyldopa (MK-486).
    Warsh JJ; Stancer HC
    Eur J Pharmacol; 1975 May; 32(1):128-32. PubMed ID: 1080116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The origin of blood k-hydroxyindoleacetic acid following L-hydrazino-alpha-methyldopa (MK-486).
    Warsh JJ; Stancer HC
    Eur J Pharmacol; 1975 May; 32(1):128-32. PubMed ID: 1080115
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Methylation of exogenous 3,4-dihydroxyphenylalanine (,dopa)--effects on methyl group metabolism.
    Ordonez LA; Wurtman RJ
    Biochem Pharmacol; 1973 Jan; 22(1):134-7. PubMed ID: 4763241
    [No Abstract]   [Full Text] [Related]  

  • 48. Renal dopamine synthesis from precursors.
    Barthelmebs M; Vailly B; Velly J; Ehrhardt JD; Grima M; Imbs JL
    Am J Hypertens; 1990 Jun; 3(6 Pt 2):18S-21S. PubMed ID: 2116809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H
    Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
    [No Abstract]   [Full Text] [Related]  

  • 50. [On the formation of H-3-dopa from H-3-tyrosine and determination of the dopa synthesis rate in the fowl and cat adrenal gland under in vivo conditions].
    Hempel K; Männl HF
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1967; 257(4):391-408. PubMed ID: 4232726
    [No Abstract]   [Full Text] [Related]  

  • 51. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
    Watanabe AM; Parks LC; Kopin IJ
    J Clin Invest; 1971 Jun; 50(6):1322-8. PubMed ID: 5578236
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolism and blood-brain clearance of L-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-L-DOPA in the rat.
    Cumming P; Ase A; Diksic M; Harrison J; Jolly D; Kuwabara H; Laliberté C; Gjedde A
    Biochem Pharmacol; 1995 Sep; 50(7):943-6. PubMed ID: 7575677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of benserazide on tryptophan metabolism in the mouse.
    Bender DA; Smith WR; Humm RP
    Biochem Pharmacol; 1977 Sep; 26(17):1619-23. PubMed ID: 901580
    [No Abstract]   [Full Text] [Related]  

  • 54. Modulatory effects of L-DOPA on D2 dopamine receptors in rat striatum, measured using in vivo microdialysis and PET.
    Opacka-Juffry J; Ashworth S; Ahier RG; Hume SP
    J Neural Transm (Vienna); 1998; 105(4-5):349-64. PubMed ID: 9720967
    [TBL] [Abstract][Full Text] [Related]  

  • 55. D-dopa is unidirectionally converted to L-dopa by D-amino acid oxidase, followed by dopa transaminase.
    Wu M; Zhou XJ; Konno R; Wang YX
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1042-6. PubMed ID: 17042912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
    Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS
    Drugs; 1976; 11(5):329-77. PubMed ID: 782834
    [No Abstract]   [Full Text] [Related]  

  • 57. Transamination of aromatic amino acids in rat liver and brain.
    Puzyńska L
    Acta Biochim Pol; 1972; 19(2):95-108. PubMed ID: 4402582
    [No Abstract]   [Full Text] [Related]  

  • 58. Monoamine precursors and copulatory behavior in the male rat.
    Malmnäs CO
    Acta Physiol Scand Suppl; 1973; 400():47-68. PubMed ID: 4546480
    [No Abstract]   [Full Text] [Related]  

  • 59. [Somatosensory evoked potentials in patients with parkinsonism during L-dopa decarboxylase inhibitor treatment].
    Koziel H; Kuran W; Zakrzewska F
    Neurol Neurochir Pol; 1977; 11(1):73-80. PubMed ID: 840365
    [No Abstract]   [Full Text] [Related]  

  • 60. The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography.
    Hoffman JM; Melega WP; Hawk TC; Grafton SC; Luxen A; Mahoney DK; Barrio JR; Huang SC; Mazziotta JC; Phelps ME
    J Nucl Med; 1992 Aug; 33(8):1472-7. PubMed ID: 1634937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.